Santen Pharmaceutical Co., Ltd.
SNPHF · OTC
3/31/2025 | 3/31/2024 | 3/31/2023 | 3/31/2022 | |
|---|---|---|---|---|
| Operating Activities | – | – | – | – |
| Net Income | $36,256,000 | $26,642,000 | -$14,983,000 | $27,189,000 |
| Dep. & Amort. | $17,948,000 | $18,178,000 | $17,249,000 | $17,055,000 |
| Deferred Tax | $0 | $0 | $0 | $0 |
| Stock-Based Comp. | $0 | $0 | $0 | $0 |
| Change in WC | $10,209,000 | $14,168,000 | -$5,059,000 | $4,706,000 |
| Other Non-Cash | -$3,485,000 | $13,661,000 | $39,940,000 | -$2,907,000 |
| Operating Cash Flow | $60,928,000 | $72,649,000 | $37,147,000 | $46,043,000 |
| Investing Activities | – | – | – | – |
| PP&E Inv. | -$6,662,000 | -$9,319,000 | -$24,588,000 | -$35,841,000 |
| Net Acquisitions | $0 | -$207,000 | -$3,470,000 | -$2,969,000 |
| Inv. Purchases | $0 | -$301,000 | -$589,000 | -$1,067,000 |
| Inv. Sales/Matur. | $0 | $4,127,000 | $2,149,000 | $3,870,000 |
| Other Inv. Act. | -$1,561,000 | -$445,000 | -$279,000 | $838,000 |
| Investing Cash Flow | -$8,223,000 | -$6,145,000 | -$26,777,000 | -$35,169,000 |
| Financing Activities | – | – | – | – |
| Debt Repay. | -$3,313,000 | -$2,112,000 | $4,356,000 | $20,460,000 |
| Stock Issued | $0 | $0 | $0 | $0 |
| Stock Repurch. | -$37,883,000 | -$16,962,000 | -$26,007,000 | -$12,000 |
| Dividends Paid | -$12,111,000 | -$11,881,000 | -$12,607,000 | -$11,994,000 |
| Other Fin. Act. | $0 | -$3,076,000 | -$2,962,000 | -$2,897,000 |
| Financing Cash Flow | -$53,307,000 | -$34,031,000 | -$37,220,000 | $5,557,000 |
| Forex Effect | -$983,000 | $4,206,000 | $1,739,000 | $3,694,000 |
| Net Chg. in Cash | $92,997,000 | $36,679,000 | -$25,111,000 | $20,126,000 |
| Supplemental Information | – | – | – | – |
| Beg. Cash | $94,582,000 | $57,903,000 | $83,014,000 | $62,888,000 |
| End Cash | $92,997,000 | $94,582,000 | $57,903,000 | $83,014,000 |
| Free Cash Flow | $54,266,000 | $61,962,000 | $12,559,000 | $10,202,000 |